Therachon

Expands Pfizer’s rare disease portfolio with potential first-in-class therapy for achondroplasia, a genetic condition and the most common form... Read More

Therachon Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating TA-46, a Novel Investigational Therapy for the Potential Treatment of Achondroplasia

February 14, 2018
clinical trial
TA-46
therachon

BASEL, Switzerland, February 14, 2018 – Therachon AG, a biotechnology company focused on rare genetic diseases, today announced the dosing... Read More

Therachon

Therachon Receives EMA and FDA Orphan Drug Designation for TA-46 for Achondroplasia

June 20, 2017
TA-46
therachon

BASEL, Switzerland — June 20, 2017 – Therachon AG, a biotechnology company focused on rare genetic diseases, announced today that... Read More

Category: Therachon

Therachon

Pfizer Acquires Clinical-Stage Biotech Therachon

Therachon

Therachon Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating TA-46, a Novel Investigational Therapy for the Potential Treatment of Achondroplasia

Therachon

Therachon Receives EMA and FDA Orphan Drug Designation for TA-46 for Achondroplasia